When was Magnolia Neurosciences founded?

Magnolia Neurosciences was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Magnolia Neurosciences located?

Magnolia Neurosciences is headquartered in New York City, United States.

How many employees does Magnolia Neurosciences have?

As of Jul 01, 2024, the latest employee count at Magnolia Neurosciences is 6.

Is Magnolia Neurosciences a funded company?

Magnolia Neurosciences is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Aug 13, 2018.

When was the latest funding round of Magnolia Neurosciences?

Magnolia Neurosciences' latest funding was a $***** Series A round on Aug 13, 2018, with participation from 10 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.63B in funding in 2026 to date.

Where does Magnolia Neurosciences rank among its competitors?

Magnolia Neurosciences ranks 211th amongst 458 active competitors, of which 161 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Magnolia Neurosciences?

Magnolia Neurosciences' top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Alchemab secured the most recent funding round in July, 2026.

Magnolia Neurosciences - 2026 Company Profile, Funding & Competitors

Company Details

Magnolia Neurosciences is developing neurodegenerative diseases and neuronal injuries. They are developing their lead candidate (proprietary neuroprotective therapy) for the prevention of neuronal cell death. The candidate is in phase I clinical trial. The company is planning to initiate the phase IIa clinical trial in the second half of 2019.

Website: magnolianeurosciences.com
Email ID: *****@magnolianeurosciences.com

Key Metrics

Founded Year

2018

Location

New York City, United States

Stage

Deadpooled

Total Funding

$31M in 1 round

Latest Funding Round

Series A, Aug 13, 2018, $*****

Investors

Arch Venture Partners & 11 more

Ranked

211^th among 458 active competitors

Employee Count

6 as on Jul 01, 2024

Similar Companies

Denali Therapeutics & 568 more

View Magnolia Neurosciences' full profile

Magnolia Neurosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MAGNOLIA NEUROSCIENCES CORPORATION CIN: - , Belgium, Active	Apr 17, 2018	-	-	-

Magnolia Neurosciences has raised a total funding of $31M over 1 round. Its latest funding round was a Series A round on Aug 13, 2018 for $*****. 10 investors participated in its latest round. Magnolia Neurosciences has 12 institutional investors.

Here is the list of recent funding rounds of Magnolia Neurosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 13, 2018	8303120	Series A	4299901	2539867	1329523	2508756

Access funding benchmarks and valuations. Sign up today!

View details of Magnolia Neurosciences's funding rounds and investors

Magnolia Neurosciences' employee count trend

Magnolia Neurosciences has 6 employees as of Jul 24. Here is Magnolia Neurosciences's employee count trend over the years:

Employee count trend for Magnolia Neurosciences

Uncover Magnolia Neurosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Magnolia Neurosciences include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Magnolia Neurosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
211th	Magnolia Neurosciences 2018, New York City (United States), Deadpooled	Developer of therapies for treating neurodegenerative diseases and neuronal injuries	$31M	Acks, AbbVie & 10 others	33/100